Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 4/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | STK4 | Q13043 | 4/20 | 0.35 |
| ▸ | STK3 | Q13188 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928284 | 0.84 | CHEK1 (0.42) | CHEK1TSHRLRRK2ALOX15AKT1 | |
| SCHEMBL30974955 | 0.82 | ALOX15 (0.51) | CHEK1TSHRKDM4EHTTLRRK2 | |
| SCHEMBL9928271 | 0.82 | LRRK2 (0.36) | TSHRKDM4EALDH1A1GAAHTT | |
| SCHEMBL9928285 | 0.78 | CHEK1 (0.37) | CHEK1LRRK2ALOX15AKT1DRD4 | |
| SCHEMBL9928283 | 0.77 | DRD2 (0.46) | CHEK1TSHRALDH1A1LRRK2HRH3 | |
| SCHEMBL9928286 | 0.75 | CHEK1 (0.40) | CHEK1LRRK2ALOX15AKT1DRD4 | |
| SCHEMBL9897735 | 0.73 | EGFR (0.49) | LRRK2 | |
| SCHEMBL9943114 | 0.72 | BTK (0.36) | ALOX15AKT1DRD4DRD2DRD3 | |
| SCHEMBL9928287 | 0.71 | CHEK1 (0.40) | CHEK1LRRK2ALOX15AKT1STK4 | |
| SCHEMBL9943132 | 0.69 | NPFFR1 (0.37) | AKT1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | CHEK1 259/4885TSHR 178/4885KDM4E 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.